The tumor embolization devices market size has grown strongly in recent years. It will grow from $1.58 trillion in 2025 to $1.73 trillion in 2026 at a compound annual growth rate (CAGR) of 9.1%. The growth in the historic period can be attributed to expansion of interventional oncology practices, rising incidence of solid tumors, increasing adoption of minimally invasive procedures, availability of advanced catheter technologies, growing use of embolization in cancer care.
The tumor embolization devices market size is expected to see strong growth in the next few years. It will grow to $2.46 trillion in 2030 at a compound annual growth rate (CAGR) of 9.2%. The growth in the forecast period can be attributed to increasing investments in interventional oncology, rising demand for combination cancer therapies, expansion of targeted drug delivery techniques, growing focus on organ-sparing treatments, increasing integration of imaging-guided interventions. Major trends in the forecast period include increasing adoption of targeted embolization therapies, rising demand for drug-eluting embolic agents, growing use of image-guided embolization procedures, expansion of minimally invasive oncology interventions, enhanced focus on precision tumor targeting.
The rise in the number of cancer cases globally is expected to drive the growth of the tumor embolization devices market during the forecast period. Cancer is a disease characterized by the uncontrolled growth of abnormal cells that can invade or spread to other parts of the body. The increasing incidence of cancer is largely attributed to aging populations, as older individuals face a higher risk due to accumulated genetic mutations and prolonged exposure to risk factors. Tumor embolization devices help address this growing burden by enabling targeted, minimally invasive treatments that block blood flow to tumors, thereby restricting tumor growth and improving patient outcomes. For instance, in 2023, according to the American Cancer Society Inc., a US-based non-profit organization, approximately 1,958,310 new cancer cases were diagnosed in the United States, up from about 1,918,030 new cases in 2022. Therefore, the rising global incidence of cancer is anticipated to boost demand for tumor embolization devices over the coming years.
The increase in healthcare expenditures is expected to drive the growth of the tumor embolization devices market going forward. Healthcare expenditures include all costs related to the provision of healthcare services, such as family planning, nutrition programs, and emergency health assistance. Rising healthcare spending supports the development and adoption of a wide range of healthcare products, including tumor embolization devices. For instance, in May 2023, according to a report published by the Office for National Statistics, a UK-based government department, healthcare spending in the UK grew by 5.6% between 2022 and 2023, compared with growth of 0.9% in 2022. UK healthcare expenditure amounted to approximately $317.63 billion (£292 billion) in 2023. Therefore, the rise in healthcare expenditures is contributing to the growth of the tumor embolization devices market.
Major companies in the tumor embolization devices market are emphasizing the introduction of innovative treatments, such as Eye90, to maximize market revenue. Eye90 microspheres are a Y90 radioembolization device specifically designed for the treatment of liver tumors, particularly hepatocellular carcinoma. In May 2023, ABK Biomedical, a Canada-based medical device company, obtained Investigational Device Exemption (IDE) approval from the US Food and Drug Administration (FDA) to initiate a multicenter pivotal study of Eye90 microspheres in hepatocellular carcinoma. These microspheres are produced through a proprietary manufacturing process, resulting in uniform size distribution and high radioactivity concentration. They are designed to deliver a high dose of radiation to the tumor while minimizing exposure to healthy tissue.
Major companies operating in the tumor embolization devices market are Boston Scientific Corporation, Medtronic plc, Terumo Corporation, Sirtex Medical Limited, Merit Medical Systems Inc., Cook Medical LLC, AngioDynamics Inc., Johnson & Johnson, Penumbra Inc., Teleflex Incorporated, Kaneka Corporation, Guerbet, BTI Biotechnology Institute S.L., BTG International, Avinger Inc., Shape Memory Medical Inc., Delcath Systems Inc., Endoshape Inc., InSitu Technologies Inc., Surefire Medical Inc., Varian Medical Systems Inc.
North America was the largest region in the tumor embolization devices market in 2025. Asia-Pacific was the second largest region in the tumor embolization devices market. The regions covered in the tumor embolization devices market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the tumor embolization devices market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs are impacting the tumor embolization devices market by increasing costs of imported microspheres, catheter systems, embolic materials, imaging-compatible components, and precision manufacturing equipment. Cancer treatment centers in North America and Europe are most affected due to dependence on imported specialized devices, while Asia-Pacific faces cost pressure on production and exports. These tariffs are increasing procedure costs and slowing device adoption. However, they are also encouraging domestic production, regional material sourcing, and innovation in cost-effective embolization technologies.
The tumor embolization devices market research report is one of a series of new reports that provides tumor embolization devices market statistics, including tumor embolization devices industry global market size, regional shares, competitors with a tumor embolization devices market share, detailed tumor embolization devices market segments, market trends and opportunities, and any further data you may need to thrive in the tumor embolization devices industry. This tumor embolization devices market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Tumor embolization devices are minimally invasive instruments employed in the treatment of tumors. These devices serve the purpose of either occluding the blood supply to the tumor or delivering therapeutic agents directly to the tumor site.
The primary categories of tumor embolization devices include radioembolic agents and non-radioactive embolic agents. Non-radioactive embolic agents encompass materials like gelatin foam, tris-acryl gelatin microspheres, and polyvinyl alcohol (PVA) that are utilized in the treatment of tumors. These applications are relevant to both cancerous and noncancerous tumors, and the devices are employed by various end-users, including hospitals, cancer treatment centers, intensive care units, and surgical centers.
The tumor embolization devices market consists of sales of radioembolic agents and non-radioactive embolic agents. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
The tumor embolization devices market size is expected to see strong growth in the next few years. It will grow to $2.46 trillion in 2030 at a compound annual growth rate (CAGR) of 9.2%. The growth in the forecast period can be attributed to increasing investments in interventional oncology, rising demand for combination cancer therapies, expansion of targeted drug delivery techniques, growing focus on organ-sparing treatments, increasing integration of imaging-guided interventions. Major trends in the forecast period include increasing adoption of targeted embolization therapies, rising demand for drug-eluting embolic agents, growing use of image-guided embolization procedures, expansion of minimally invasive oncology interventions, enhanced focus on precision tumor targeting.
The rise in the number of cancer cases globally is expected to drive the growth of the tumor embolization devices market during the forecast period. Cancer is a disease characterized by the uncontrolled growth of abnormal cells that can invade or spread to other parts of the body. The increasing incidence of cancer is largely attributed to aging populations, as older individuals face a higher risk due to accumulated genetic mutations and prolonged exposure to risk factors. Tumor embolization devices help address this growing burden by enabling targeted, minimally invasive treatments that block blood flow to tumors, thereby restricting tumor growth and improving patient outcomes. For instance, in 2023, according to the American Cancer Society Inc., a US-based non-profit organization, approximately 1,958,310 new cancer cases were diagnosed in the United States, up from about 1,918,030 new cases in 2022. Therefore, the rising global incidence of cancer is anticipated to boost demand for tumor embolization devices over the coming years.
The increase in healthcare expenditures is expected to drive the growth of the tumor embolization devices market going forward. Healthcare expenditures include all costs related to the provision of healthcare services, such as family planning, nutrition programs, and emergency health assistance. Rising healthcare spending supports the development and adoption of a wide range of healthcare products, including tumor embolization devices. For instance, in May 2023, according to a report published by the Office for National Statistics, a UK-based government department, healthcare spending in the UK grew by 5.6% between 2022 and 2023, compared with growth of 0.9% in 2022. UK healthcare expenditure amounted to approximately $317.63 billion (£292 billion) in 2023. Therefore, the rise in healthcare expenditures is contributing to the growth of the tumor embolization devices market.
Major companies in the tumor embolization devices market are emphasizing the introduction of innovative treatments, such as Eye90, to maximize market revenue. Eye90 microspheres are a Y90 radioembolization device specifically designed for the treatment of liver tumors, particularly hepatocellular carcinoma. In May 2023, ABK Biomedical, a Canada-based medical device company, obtained Investigational Device Exemption (IDE) approval from the US Food and Drug Administration (FDA) to initiate a multicenter pivotal study of Eye90 microspheres in hepatocellular carcinoma. These microspheres are produced through a proprietary manufacturing process, resulting in uniform size distribution and high radioactivity concentration. They are designed to deliver a high dose of radiation to the tumor while minimizing exposure to healthy tissue.
Major companies operating in the tumor embolization devices market are Boston Scientific Corporation, Medtronic plc, Terumo Corporation, Sirtex Medical Limited, Merit Medical Systems Inc., Cook Medical LLC, AngioDynamics Inc., Johnson & Johnson, Penumbra Inc., Teleflex Incorporated, Kaneka Corporation, Guerbet, BTI Biotechnology Institute S.L., BTG International, Avinger Inc., Shape Memory Medical Inc., Delcath Systems Inc., Endoshape Inc., InSitu Technologies Inc., Surefire Medical Inc., Varian Medical Systems Inc.
North America was the largest region in the tumor embolization devices market in 2025. Asia-Pacific was the second largest region in the tumor embolization devices market. The regions covered in the tumor embolization devices market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the tumor embolization devices market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs are impacting the tumor embolization devices market by increasing costs of imported microspheres, catheter systems, embolic materials, imaging-compatible components, and precision manufacturing equipment. Cancer treatment centers in North America and Europe are most affected due to dependence on imported specialized devices, while Asia-Pacific faces cost pressure on production and exports. These tariffs are increasing procedure costs and slowing device adoption. However, they are also encouraging domestic production, regional material sourcing, and innovation in cost-effective embolization technologies.
The tumor embolization devices market research report is one of a series of new reports that provides tumor embolization devices market statistics, including tumor embolization devices industry global market size, regional shares, competitors with a tumor embolization devices market share, detailed tumor embolization devices market segments, market trends and opportunities, and any further data you may need to thrive in the tumor embolization devices industry. This tumor embolization devices market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Tumor embolization devices are minimally invasive instruments employed in the treatment of tumors. These devices serve the purpose of either occluding the blood supply to the tumor or delivering therapeutic agents directly to the tumor site.
The primary categories of tumor embolization devices include radioembolic agents and non-radioactive embolic agents. Non-radioactive embolic agents encompass materials like gelatin foam, tris-acryl gelatin microspheres, and polyvinyl alcohol (PVA) that are utilized in the treatment of tumors. These applications are relevant to both cancerous and noncancerous tumors, and the devices are employed by various end-users, including hospitals, cancer treatment centers, intensive care units, and surgical centers.
The tumor embolization devices market consists of sales of radioembolic agents and non-radioactive embolic agents. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
Table of Contents
1. Executive Summary
2. Tumor Embolization Devices Market Characteristics
3. Tumor Embolization Devices Market Supply Chain Analysis
4. Global Tumor Embolization Devices Market Trends and Strategies
5. Tumor Embolization Devices Market Analysis of End Use Industries
7. Global Tumor Embolization Devices Strategic Analysis Framework, Current Market Size, Market Comparisons and Growth Rate Analysis
8. Global Tumor Embolization Devices Total Addressable Market (TAM) Analysis for the Market
9. Tumor Embolization Devices Market Segmentation
10. Tumor Embolization Devices Market Regional and Country Analysis
11. Asia-Pacific Tumor Embolization Devices Market
12. China Tumor Embolization Devices Market
13. India Tumor Embolization Devices Market
14. Japan Tumor Embolization Devices Market
15. Australia Tumor Embolization Devices Market
16. Indonesia Tumor Embolization Devices Market
17. South Korea Tumor Embolization Devices Market
18. Taiwan Tumor Embolization Devices Market
19. South East Asia Tumor Embolization Devices Market
20. Western Europe Tumor Embolization Devices Market
21. UK Tumor Embolization Devices Market
22. Germany Tumor Embolization Devices Market
23. France Tumor Embolization Devices Market
24. Italy Tumor Embolization Devices Market
25. Spain Tumor Embolization Devices Market
26. Eastern Europe Tumor Embolization Devices Market
27. Russia Tumor Embolization Devices Market
28. North America Tumor Embolization Devices Market
29. USA Tumor Embolization Devices Market
30. Canada Tumor Embolization Devices Market
31. South America Tumor Embolization Devices Market
32. Brazil Tumor Embolization Devices Market
33. Middle East Tumor Embolization Devices Market
34. Africa Tumor Embolization Devices Market
36. Tumor Embolization Devices Market Competitive Landscape and Company Profiles
37. Tumor Embolization Devices Market Other Major and Innovative Companies
40. Tumor Embolization Devices Market High Potential Countries, Segments and Strategies
41. Appendix
List of Tables
Executive Summary
Tumor Embolization Devices Market Global Report 2026 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses tumor embolization devices market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
- Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on end user analysis.
- Benchmark performance against key competitors based on market share, innovation, and brand strength.
- Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
- Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for tumor embolization devices? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The tumor embolization devices market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
- The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
- The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
- The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
- The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
- The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
- Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.
Report Scope
Markets Covered:
1) By Type: Radioembolic Agents; Non-radioactive Embolic Agents2) By Application: Cancer Tumors; Noncancerous Tumors
3) By End User: Hospitals; Cancer Treatment Centers; Intensive Care Units; Surgical Centers
Subsegments:
1) By Radioembolic Agents: Yttrium-90 (Y-90) Microspheres; Holmium-166 Microspheres2) By Non-radioactive Embolic Agents: Drug-Eluting Beads (DEBs); Microspheres (Polyvinyl Alcohol - PVA Particles); Gelatin Sponges; Liquid Embolic Agents (Onyx, Glue-Based Agents)
Companies Mentioned: Boston Scientific Corporation; Medtronic plc; Terumo Corporation; Sirtex Medical Limited; Merit Medical Systems Inc.; Cook Medical LLC; AngioDynamics Inc.; Johnson & Johnson; Penumbra Inc.; Teleflex Incorporated; Kaneka Corporation; Guerbet; BTI Biotechnology Institute S.L.; BTG International; Avinger Inc.; Shape Memory Medical Inc.; Delcath Systems Inc.; Endoshape Inc.; InSitu Technologies Inc.; Surefire Medical Inc.; Varian Medical Systems Inc.
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: Word, PDF or Interactive Report + Excel Dashboard
Added Benefits:
- Bi-Annual Data Update
- Customisation
- Expert Consultant Support
Companies Mentioned
The companies featured in this Tumor Embolization Devices market report include:- Boston Scientific Corporation
- Medtronic plc
- Terumo Corporation
- Sirtex Medical Limited
- Merit Medical Systems Inc.
- Cook Medical LLC
- AngioDynamics Inc.
- Johnson & Johnson
- Penumbra Inc.
- Teleflex Incorporated
- Kaneka Corporation
- Guerbet
- BTI Biotechnology Institute S.L.
- BTG International
- Avinger Inc.
- Shape Memory Medical Inc.
- Delcath Systems Inc.
- Endoshape Inc.
- InSitu Technologies Inc.
- Surefire Medical Inc.
- Varian Medical Systems Inc.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 250 |
| Published | February 2026 |
| Forecast Period | 2026 - 2030 |
| Estimated Market Value ( USD | $ 1.73 Trillion |
| Forecasted Market Value ( USD | $ 2.46 Trillion |
| Compound Annual Growth Rate | 9.2% |
| Regions Covered | Global |
| No. of Companies Mentioned | 22 |
